About Thirona
Thirona is a Healthcare company based in Nijmegen (Netherlands) founded in 2014, and was acquired by Revenio Group in August 2024. AI-based medical image analysis software is provided for diagnostics. Thirona has raised $5.37 million across 3 funding rounds from investors including Revenio Group, Heran Partners and Borski Fund. Thirona offers products and services including Thoracic CT Analysis Tool and Drug Development Platform. Its focus areas include HealthTech, Healthcare IT, Provider and Clinical Operations.
Company details
Thirona was established in 2014 in Nijmegen, Netherlands, within the healthcare technology sector. AI-driven software for medical image analysis is developed and supplied. Chest CT is utilized for quantifying lung conditions in CT scans, aiding detection and treatment of respiratory diseases. CAD4TB functions as a detection tool for tuberculosis anomalies. RetCAD identifies issues linked to age-related macular degeneration and diabetic retinopathy. Focus is placed on clinical support across imaging modalities.
- Headquarters Nijmegen, Netherlands
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website thirona.eu
- Social LinkedIn X
- Acquired by Revenio Group (Aug 2024)
- Total Equity Funding$5.37M (USD)
in 3 rounds
- Latest Funding Round$5.37M (USD), Series A
Sep 2023
- InvestorsRevenio Group
& 3 more
- Acquired byRevenio Group
(Aug 2024)
Products & Services of Thirona
Thirona offers a comprehensive portfolio of products and services, including Thoracic CT Analysis Tool and Drug Development Platform.
Analyzes lung images to quantify diseases for clinical diagnostics.
Supports trials with quantitative image analysis for treatment development.
Funding Insights of Thirona
Thirona has successfully raised a total of $5.37M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $5.37 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.37M
- Total Rounds 3
- Last Round Series A — $5.37M
- Investors Count 3
All 3 funding rounds of Thirona with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2023 | $5.37M | Series A | – | HERAN Partners, Borski Fund | – |
| Jun 2023 | $2.72M | Grant | – | – | |
| Oct 2021 | Seed | – | HERAN Partners |
4 investors in total: 4 institutional.
Investors in Thirona
Thirona has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Revenio Group, Heran Partners and Borski Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital is provided to healthcare and life sciences innovators. | heranpartners.com | Antwerp, Belgium | ||
Venture capital investments are made in diverse, gender-balanced teams. | borskifund.com | Amsterdam, Netherlands | ||
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
Diagnostic devices for medical applications are developed and commercialized. | 2001 | reveniogroup.fi | Vantaa, Finland |
Investor details for Thirona
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Thirona
1 people are tracked at Thirona (1 in leadership).
| Name | Role | Group |
|---|---|---|
Rita Priori | Chief Technology Officer | Leadership |
Complete people profiles for Thirona
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Thirona
4 dated milestones of Thirona across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Thirona is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $5.4M.
- Exit Acquired by Revenio Group.
Web traffic of Thirona
The website of Thirona (thirona.eu) receives about 4.5K visits a month.
- Monthly visits4.5K
▼ 31.6% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Thirona
Complete news archive for Thirona
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Thirona
Thirona was founded in 2014 and raised its 1st funding round 7 years after it was founded.
Thirona is headquartered in Nijmegen, Netherlands. It is registered at Nijmegen, Gelderland, Netherlands.
Thirona is a funded company, having raised a total of $5.37M across 3 funding rounds to date.
Thirona was established in 2014 in Nijmegen, Netherlands, within the healthcare technology sector. AI-driven software for medical image analysis is developed and supplied. Chest CT is utilized for quantifying lung conditions in CT scans, aiding detection and treatment of respiratory diseases. CAD4TB functions as a detection tool for tuberculosis anomalies. RetCAD identifies issues linked to age-related macular degeneration and diabetic retinopathy. Focus is placed on clinical support across imaging modalities.
Thirona offers Thoracic CT Analysis Tool and Drug Development Platform.
Thirona has 4 investors. Key investors include Revenio Group, Heran Partners, Borski Fund, and EIC Fund.
Yes. Thirona was acquired by Revenio Group in August 2024.